{"text": "Overall , due to an adverse event drug treatment was altered in 82 ( 7.9 % ) intervention participants compared with 10 ( 1.9 % ) usual care participants ( 1.1 % v 0.2 % , respectively , were withdrawn by the general practitioner or voluntarily withdrew .", "label": "", "metadata": {}, "score": "23.008028"}
{"text": "Post - randomisation , 24 ( 4.6 % ) participants in the usual care group experienced 35 serious adverse events compared with 37 ( 3.7 % ) participants and 57 serious adverse events in the intervention group ( 6.7 v 5.6 events/100 patients ) .", "label": "", "metadata": {}, "score": "30.872816"}
{"text": "Change in absolute cardiovascular risk .Safety profile .A total of 1044 adverse events were recorded in 592 ( 27.1 % ) participants during the study run - in phase , with 424 ( 40.6 % ) classified as related to treatment by the treating doctor .", "label": "", "metadata": {}, "score": "31.452374"}
{"text": "There was no difference in the number of deaths between the intervention arms in the six trials ( with 287 patients ) reporting mortality ( very low quality evidence ) .", "label": "", "metadata": {}, "score": "31.920805"}
{"text": "Only a small proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or more drugs applied in the intervention .", "label": "", "metadata": {}, "score": "31.945728"}
{"text": "Further , the patients that received adjusted therapy experienced a similar rate of adverse events as the control group ( 3.3 percent vs. 3.04 percent ) .", "label": "", "metadata": {}, "score": "32.10137"}
{"text": "Notably , 4 % of randomised participants did not have an endpoint blood pressure recorded and were excluded from endpoint analyses .The general practitioners were reluctant to try to meet the more aggressive guideline targets for blood pressure reduction and in almost 15 % of cases opted for a more lenient target , in effect making the task of achieving control easier .", "label": "", "metadata": {}, "score": "32.14671"}
{"text": "What this study adds .Despite parallel reductions in absolute cardiovascular risk , achieving more stringent blood pressure targets remains a challenge .Modification of treatment owing to adverse events was more common in the intervention group than usual care group ( 7.9 % v 1.9 % ) .", "label": "", "metadata": {}, "score": "32.255318"}
{"text": "Overall , those assigned the combination treatment arm of the intervention group had the highest rate of individual blood pressure control ( 37.9 % for the endpoint and 42.1 % at week 26 ) .", "label": "", "metadata": {}, "score": "32.54158"}
{"text": "The study 's follow - up ultrasounds revealed that GSM levels had decreased in 230 ( 40 percent ) of the patients .Of those , 85 ( 37 percent ) experienced a major adverse cardiovascular event within three years of the second ultrasound .", "label": "", "metadata": {}, "score": "33.040756"}
{"text": "The study demonstrated that there was no difference in all - cause mortality , coronary events , or any - cause hospitalization between pharmacist care and the control group .", "label": "", "metadata": {}, "score": "33.392426"}
{"text": "Overall , the number and frequency of adverse events was consistent with the nature and size of the patient cohort and the drugs being prescribed .", "label": "", "metadata": {}, "score": "35.287384"}
{"text": "The intervention in the current study brought all these elements together , with more than double ( 81 % v 40 % ) the proportion of intervention participants receiving combination therapy compared with monotherapy at 26 weeks .", "label": "", "metadata": {}, "score": "35.71445"}
{"text": "The combined application of more intensive follow - up and drug treatment is reflected in greater use of combination therapies ( prescribed as single pills ) and progressive reductions in blood pressure between six and 26 weeks in the intervention group .", "label": "", "metadata": {}, "score": "36.29309"}
{"text": "We also describe the proportion and rate of adverse events ( per participant ) .Results .Of those who entered the run - in phase , 1329 ( 60.8 % ) had pre - existing hypertension and had been treated for a median of 5 ( interquartile range 2 - 10 ) years .", "label": "", "metadata": {}, "score": "36.298843"}
{"text": "The expected trade - off between more intense blood pressure control and an increase in adverse events occurred , with more participants in the intervention group withdrawn on this basis ( 1.1 % v 0.2 % ) or requiring active change to their treatment ( 7.9 % v 1.9 % ) .", "label": "", "metadata": {}, "score": "36.518852"}
{"text": "Clinical significance of interventions was evaluated by an independent team ( 1 internist , 1 clinical pharmacologist ) using a standardized method for categorizing drug related problems ( DRPs ) .", "label": "", "metadata": {}, "score": "36.86067"}
{"text": "Serious Adverse Events and Cardiovascular Safety .The primary endpoint of the 52-week safety trial was the occurrence of all serious adverse events .", "label": "", "metadata": {}, "score": "36.915524"}
{"text": "Overall the trials were small , with only four reporting an a priori sample size calculation .No trial was powered to determine changes in mortality as a primary outcome .", "label": "", "metadata": {}, "score": "37.02451"}
{"text": "However , the difference was too small to make a difference in clinical practice .Only one included study reported adverse events as an outcome and reported no adverse events due to FFP transfusion .", "label": "", "metadata": {}, "score": "37.112568"}
{"text": "All serious adverse events and cardiovascular endpoints were adjudicated by an independent event adjudication committee .Serious adverse events occurred in 176/2054 ( 8.5 % ) CYCLOSET - treated patients and 98/1016 ( 9.6 % ) placebo - treated patients .", "label": "", "metadata": {}, "score": "37.75241"}
{"text": "Three studies were conducted in hospital , outpatients clinics , or medical offices [ 16 - 18 ] ; one study was conducted in community pharmacies [ 15 ] ; and one in both hospital and community pharmacies [ 14 ] .", "label": "", "metadata": {}, "score": "38.18154"}
{"text": "Strong recommendations for treatment adjustment were sent to investigators when patients were identified as slow responders .The remaining patients constituted the control group .In the slow responder group , 85 percent received an adjusted thienopyridine regimen after the release of the genetic profile .", "label": "", "metadata": {}, "score": "38.215366"}
{"text": "Discussion .Importantly , two thirds of the participants had a history of persistent hypertension despite receiving a typical range of antihypertensive treatments , and the remainder were unresponsive to valsartan monotherapy ; one of the most commonly prescribed antihypertensive agents globally .", "label": "", "metadata": {}, "score": "38.42183"}
{"text": "In 344 ( 60 percent ) of the patients , ultrasound GSM levels had increased between the baseline and follow - up ultrasound examinations .Of those patients , 92 ( 28 percent ) experienced a major adverse cardiovascular event .", "label": "", "metadata": {}, "score": "39.04118"}
{"text": "Description of studies and types of interventions .Table 1 summarizes the characteristics of the included studies [ 14 - 18 ] .Overall , five studies involving a total of 2568 participants compared pharmacist interventions with usual care .", "label": "", "metadata": {}, "score": "39.755123"}
{"text": "Acceptance rate by physicians was 68.4 % .Among the interventions that were rated as clinically significant , 46(48.9 % ) and 25(26.6 % ) had major and moderate clinical importance respectively .", "label": "", "metadata": {}, "score": "40.89126"}
{"text": "The study design was a prospective observational study where pharmaceutical care services provided by clinical pharmacists for inpatients were documented over a period of two months .", "label": "", "metadata": {}, "score": "40.910454"}
{"text": "However , these benefits were achieved with interventions that focused on a specific issue within CVD ( e.g. , medication adherence , prevention of adverse events ) or on one discrete cardiovascular diagnosis ( e.g. , heart failure , anticoagulation ) .", "label": "", "metadata": {}, "score": "40.98761"}
{"text": "An independent data management team at Baker IDI coordinated a standardised protocol for randomising participants over the telephone .Participants were assigned to the groups using a prespecified ratio of 1:2 for usual care versus intervention ( with a further ratio of 1:2 within the intervention arm to assign participants to a monotherapy strategy and to two possible combined treatment strategies ) .", "label": "", "metadata": {}, "score": "41.18871"}
{"text": "Cardiac Adverse Reactions .In the pooled , placebo - controlled studies , the proportion of patients with serious cardiovascular reactions was 1.7 % and 1.3 % in the Rituxan and placebo treatment groups , respectively .", "label": "", "metadata": {}, "score": "41.270626"}
{"text": "One study compared therapeutic use of two types of plasma .The timing of intervention varied , including FFP transfusion at the time of heparin neutralisation and stopping cardiopulmonary bypass ( CPB ) ( seven trials ) , with CPB priming ( four trials ) , after anaesthesia induction ( one trial ) and postoperatively ( two trials ) .", "label": "", "metadata": {}, "score": "41.285133"}
{"text": "In conclusion , this post hoc analysis of a pharmacist in- tervention to improve medication use in adult outpa- tients suggests a lower risk of adverse drug events and medication errors .", "label": "", "metadata": {}, "score": "41.773262"}
{"text": "Hope C , Overhage JM , Seger A , et al .A tiered approach is more cost effective thantraditionalpharmacist - basedreviewforclassifyingcomputer - detectedsig- nals as adverse drug events .", "label": "", "metadata": {}, "score": "41.958267"}
{"text": "We carried out efficacy analyses on an intention to treat population , consisting of all participants randomised to the intervention arm or to the usual care arm and who had at least one recorded blood pressure measurement after randomisation .", "label": "", "metadata": {}, "score": "42.19057"}
{"text": "Fourteen studies compared prophylactic FFP against no FFP and one study compared two types of FFP , both used therapeutically .No studies reported on all outcomes .", "label": "", "metadata": {}, "score": "42.416306"}
{"text": "In the 52-week safety trial , the incidence of hypoglycemia was 6.9 % among the CYCLOSET - treated patients and 5.3 % among the placebo - treated patients .", "label": "", "metadata": {}, "score": "42.58986"}
{"text": "Only one included study reported adverse events as an outcome and reported no significant adverse events following FFP transfusion .Desborough M , Sandu R , Brunskill SJ , Doree C , Trivella M , Montedori A , Abraha I , Stanworth S. Fresh frozen plasma for cardiovascular surgery .", "label": "", "metadata": {}, "score": "42.78295"}
{"text": "The study was independently monitored by routine visits , and case report forms were verified against clinical records for 20 % of patients .We used standardised operating procedures for data queries and management .", "label": "", "metadata": {}, "score": "43.072258"}
{"text": "Since medication nonadherence is associated with an increased rate of subsequent cardiovascular events and mortality [ 6 - 10 ] , improvements in medication adherence will lead to clinically important reductions in recurrent myocardial infarctions and death .", "label": "", "metadata": {}, "score": "43.091915"}
{"text": "The authors also sug - gested that augmenting medication systems by adding dynamic renal dosing alerts would improve moni - toring .Summary : A comparison of suggested renal dosing and actual dosing at hospital discharge revealed that appropriate prescribing may be overlooked .", "label": "", "metadata": {}, "score": "43.119884"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .\" Interacting with the health care team in patient rounds , interviewing patients and conducting medication histories ; providing recommendations on drug selection and follow - up all resulted in improved outcomes 2 3 Murray et al .", "label": "", "metadata": {}, "score": "43.41978"}
{"text": "However , based on a computed tomography , or CT , scan , the principal investigator subsequently found evidence against the occurrence of a stroke and concluded that the events resulting in the patient 's death were unlikely related to OCA treatment .", "label": "", "metadata": {}, "score": "43.434074"}
{"text": "However , there are risks of side effects from fresh frozen plasma , such as severe allergic reactions or breathing problems .We searched scientific sources to identify eligible trials and found 15 studies with 755 patients .", "label": "", "metadata": {}, "score": "43.707848"}
{"text": "Second , the design of this study was quite different from the others , where all of the patients received a disease management program from a clinical pharmacy specialist and had achieved target cholesterol values before randomization .", "label": "", "metadata": {}, "score": "43.750153"}
{"text": "Murray MD , Young J , Hoke S , et al .Pharmacist intervention to improve medi- cation adherence in heart failure : a randomized trial .", "label": "", "metadata": {}, "score": "44.017"}
{"text": "Infections .In the pooled , placebo - controlled studies , 39 % of patients in the Rituxan group experienced an infection of any type compared to 34 % of patients in the placebo group .", "label": "", "metadata": {}, "score": "44.40599"}
{"text": "EVENT IDENTIFICATION AND VERIFICATION Thecomputermonitoridentified1029triggersthatwere further analyzed for evidence of ADEs and MEs .Of the 210 events , the 5 most common , occurring in a total of 68 participants , included receipt of a prescrip- tionforadrugthatshouldbeavoidedinelderlypatients Table 1 .", "label": "", "metadata": {}, "score": "44.523064"}
{"text": "This included 196 ( 57.8 % ) participants allocated to the monotherapy arm and 355 ( 54.7 % ) to the combination therapy arm ; this compared with 246 ( 48.8 % ) participants in the usual care group .", "label": "", "metadata": {}, "score": "44.896545"}
{"text": "Acute coronary syndrome patients that carry a CYP2C19 gene variant poorly metabolize the drug .These patients are known as slow responders and exhibit a higher one year risk of major ischemic events following PCI .", "label": "", "metadata": {}, "score": "44.911915"}
{"text": "For example , nurse led interventions that comprise a structured care algorithm are associated with greater reductions in blood pressure levels than usual care overall .", "label": "", "metadata": {}, "score": "44.98584"}
{"text": "Seventy - one percent of CLL patients received 6 cycles and 90 % received at least 3 cycles of Rituxan - based therapy .Infusion Reactions .", "label": "", "metadata": {}, "score": "45.010376"}
{"text": "Further studies are needed to confirm this finding .Full - text .Inpatient studies suggest that a pharmacist may reduce these events , but outpa- tient studies have not been forthcoming .", "label": "", "metadata": {}, "score": "45.016872"}
{"text": "Staessen JA , Den Hond E , Celis H , Fagard R , Keary L , Vandenhoven G , et al .Antihypertensive treatment based on blood pressure measurement at home or in the physician 's office : a randomized controlled trial .", "label": "", "metadata": {}, "score": "45.194122"}
{"text": "Infections .In the active - controlled , double - blind study , 62 % ( 61/99 ) of patients in the Rituxan group experienced an infection of any type compared to 47 % ( 46/98 ) patients in the cyclophosphamide group by Month 6 .", "label": "", "metadata": {}, "score": "45.21067"}
{"text": "Adverse drug events and medication errors are threats to quality care .Inpatient studies suggest that a pharmacist may reduce these events , but outpatient studies have not been forthcoming .", "label": "", "metadata": {}, "score": "45.257294"}
{"text": "At baseline in the usual care group , 367 ( 70.0 % ) participants were still receiving valsartan 80 mg / day and 67 ( 12.8 % ) were receiving the increased dose of 160 mg / day .", "label": "", "metadata": {}, "score": "45.3061"}
{"text": "Thus our randomised cohort represented a more \" challenging \" group of patients with hypertension .Clinical implications .Several important issues highlighted by this pragmatic study involving more than 250 general practitioners are relevant to clinical practice guidelines and health policy in Australia and other high income countries where hypertension remains a problem .", "label": "", "metadata": {}, "score": "45.325684"}
{"text": "Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice .", "label": "", "metadata": {}, "score": "45.54477"}
{"text": "Our systematic review , identified five RCTs ( 2568 patients ) assessing the effects of pharmacist care in the secondary prevention of CHD .The ' dose ' , ' duration ' , method and outcome of pharmacist intervention varied across the studies .", "label": "", "metadata": {}, "score": "45.55349"}
{"text": "Certainly these agents targeting the renin - angiotensin system represent some of the most commonly applied in clinical practice internationally , and the treatment regimen is broadly consistent with the NICE guidelines ( phase 3 ) for people with hypertension who do not respond to initial monotherapy .", "label": "", "metadata": {}, "score": "45.615864"}
{"text": "If this occurred , the participant was rested for three minutes and the procedure repeated .Given the size and nature of the study , it was impractical to obtain independent , blinded blood pressure levels .", "label": "", "metadata": {}, "score": "45.89226"}
{"text": "However , the NIDDK has advised us that while the incidence of the serious cardiovascular events was numerically higher in the patients receiving OCA therapy , it was not statistically significantly different as compared to the placebo group .", "label": "", "metadata": {}, "score": "45.906174"}
{"text": "Table 1 .Values are numbers ( percentages ) of participants unless stated otherwise .Patterns of blood pressure management .Drug treatment after randomisation was recorded in 501 participants ( 95.6 % ) in the usual care arm and 991 ( 95.5 % ) in the intervention arm .", "label": "", "metadata": {}, "score": "46.272823"}
{"text": "We took care to note whether FFP was used therapeutically or prophylactically within each trial .Main results : .We included 15 trials , with a total of 755 participants for analysis in the review .", "label": "", "metadata": {}, "score": "46.537117"}
{"text": "The groups were well matched for clinical and personal characteristics and prespecified blood pressure targets .At randomisation , 219 ( 14.0 % with equal proportions in each group ) were assigned to a blood pressure target that differed from the recommended ( automated ) clinical profile ; these reflected general practitioners ' discretion for a mostly higher blood pressure target than recommended .", "label": "", "metadata": {}, "score": "46.800194"}
{"text": "Two studies reported changes in lipid profiles in accordance with certain previous studies [ 16 , 18 ] and both of these studies reported a greater reduction in LDL - C levels with pharmacist care compared to controls .", "label": "", "metadata": {}, "score": "46.86898"}
{"text": "The results of the present study therefore strengthen the conclusions of a recently updated Cochrane review recommending a stepped and intensive approach to the management of hypertension in primary care ; particularly in those participants who remain hypertensive despite initial treatment .", "label": "", "metadata": {}, "score": "46.93706"}
{"text": "Our primary outcome was death within 30 days after surgery .Six trials ( with 287 patients ) looked at this outcome and found no clear difference in mortality between the treatment arms but the quality of the evidence was very low .", "label": "", "metadata": {}, "score": "47.004837"}
{"text": "[ See BOXED WARNING , WARNINGS AND PRECAUTIONS ] .For Cycles 2 - 8 , the incidence of Grade 3 - 4 infusion reactions on the day of or day after the 90-minute infusion , was 2.8 % ( 95 % CI [ 1.3 % , 5.0 % ] ) .", "label": "", "metadata": {}, "score": "47.140167"}
{"text": "Cardiovascular medications , mean ( SD ) , No .Healthcare system encounters , mean ( SD ) , No . .001aParticipants in the complicated strata had a prior diagnosis of heart failure , coronary heart disease , myocardial infarction , stroke , or renal insufficiency , whereas those in the uncomplicated group had hypertension but no evidence of a prior vascular event or complication .", "label": "", "metadata": {}, "score": "47.141197"}
{"text": "Strengths and limitations of this study .The intervention directly addressed the difficult challenge of optimising blood pressure control in a real world general practice setting using commonly prescribed forms of antihypertensive agents .", "label": "", "metadata": {}, "score": "47.284657"}
{"text": "Syncope .In combined phase 2 and 3 clinical trials , syncope was reported in 1.4 % of the 2,500 CYCLOSET - treated patients and 0.6 % of the 1,454 placebo - treated patients .", "label": "", "metadata": {}, "score": "47.50076"}
{"text": "Infusion Reactions .Infusion - related reactions in the active - controlled , double - blind study were defined as any adverse event occurring within 24 hours of an infusion and considered to be infusion - related by investigators .", "label": "", "metadata": {}, "score": "47.511726"}
{"text": "Adverse drug events occurred in 121 participants ( 15.1 % ) in the control and intervention groups .Fewer ADEs were observed in the intervention group .", "label": "", "metadata": {}, "score": "47.515778"}
{"text": "Infusion - related reactions included cytokine release syndrome , flushing , throat irritation , and tremor .In the Rituxan group , the proportion of patients experiencing an infusion related reaction was 12 % , 5 % , 4 % , and 1 % following the first , second , third , and fourth infusions , respectively .", "label": "", "metadata": {}, "score": "47.51725"}
{"text": "First , as there are only a few trials available , with insufficient numbers of participants , there may not be adequate statistical power to detect clinical differences .", "label": "", "metadata": {}, "score": "47.6177"}
{"text": "Participants in the control group received usual care at the same pharmacy from nonintervention pharmacists who did not have access to the study computer , instructional materials , or the study computer monitoring program .", "label": "", "metadata": {}, "score": "47.783386"}
{"text": "In Study 4 , patients in the R - CVP arm experienced a higher incidence of infusional toxicity and neutropenia compared to patients in the CVP arm .", "label": "", "metadata": {}, "score": "47.854263"}
{"text": "Most importantly , however , we have shown that a structured blood pressure management approach ( computer assisted ) results in higher blood pressure control rates in a primary care setting .", "label": "", "metadata": {}, "score": "47.89099"}
{"text": "The control group received usual care .Main outcome measures The primary outcome was individual blood pressure target achieved at 26 weeks .Secondary outcomes were change in mean sitting systolic and diastolic blood pressure , absolute risk for cardiovascular disease within five years based on the Framingham risk score , and proportion and rate of adverse events .", "label": "", "metadata": {}, "score": "48.013454"}
{"text": "High risks of bias existed in selection , performance and detection in the cluster RCT study [ 18 ] .Primary outcomes .Mortality , cardiac events , and hospitalizations .", "label": "", "metadata": {}, "score": "48.344604"}
{"text": "AdditionalContributions : JamesYoung , PharmD , served as intervention pharmacist .REFERENCES 1 .Johnson JA , Bootman JL .Drug - related morbidity and mortality : a cost - of- illness model .", "label": "", "metadata": {}, "score": "48.47534"}
{"text": "This approach can likely be generalized to other health care settings in the country to improve medication outcomes .\" Utilizing a multidisciplinary approach to manage patients with CVD is endorsed by the American Heart Association3 and may be one mechanism to improve treatment outcomes .", "label": "", "metadata": {}, "score": "48.507904"}
{"text": "There was a difference in prothrombin time within two hours of FFP transfusion in eight trials ( with 210 patients ; moderate quality evidence ) favouring the FFP arm : MD -0.71 seconds ( 95 % CI -1.28 to -0.13 seconds ) .", "label": "", "metadata": {}, "score": "48.68598"}
{"text": "a Adverse reactions observed up to 12 months following Rituxan .b Adverse reactions graded for severity by NCI - CTC criteria .In these single - arm Rituxan studies , bronchiolitis obliterans occurred during and up to 6 months after Rituxan infusion .", "label": "", "metadata": {}, "score": "48.944077"}
{"text": "From these studies , 938 patients treated with Rituxan ( 2 x 1000 mg ) or placebo have been pooled ( see Table 2 ) .", "label": "", "metadata": {}, "score": "48.963684"}
{"text": "We compared the primary endpoint measure ( blood pressure control at week 26 ) between the study groups using a log binomial generalised linear model with stratification status at randomisation as a covariate .", "label": "", "metadata": {}, "score": "49.39479"}
{"text": "Usual care plus laboratory reminder letters .The occurrence of coronary events , mortality , and hospitalization ; medication adherence , BP control , and lipid management . cluster RCT , 6.5 months of active treatment , and 18 months of follow - up .", "label": "", "metadata": {}, "score": "49.4789"}
{"text": "Throughout the study we used a standardised protocol based on national guidelines to record blood pressure measurements .6 After participants had rested for at least five minutes and while they were seated we obtained three blood pressure measurements separated by one minute intervals using an appropriate sized cuff and a calibrated , semiautomated oscillometric device approved by the Therapeutic Goods Administration of Australia .", "label": "", "metadata": {}, "score": "49.527954"}
{"text": "In its 10-K , Intercept provides additional information on NASH and OCA to put the cardiac adverse events into perspective -- and to downplay their significance .", "label": "", "metadata": {}, "score": "49.60574"}
{"text": "Thirty - seven percent of patients evaluated during the study period ( 237/647 ) had a creatinine clear - ance less than 51 mL / min/1.73 m 2 ; dosage adjustment was warranted in 23.9 % ( 411/1,718 ) of prescrip - tions .", "label": "", "metadata": {}, "score": "49.68281"}
{"text": "Four HACA positive patients had serious infusion reactions , and the temporal relationship between HACA positivity and infusion reaction was variable .A total of 23/99 ( 23 % ) Rituxan - treated patients with GPA and MPA tested positive for HACA by 18 months .", "label": "", "metadata": {}, "score": "49.778732"}
{"text": "Wherever possible we minimised these factors by implementing a 28 day standardised treatment and blood pressure monitoring run - in phase , applying a standardised protocol for blood pressure monitoring and undertaking independent clinical auditing for data verification .", "label": "", "metadata": {}, "score": "49.929237"}
{"text": "CAD patients ( AMI , CABG , PCI ) who had been enrolled in the CPCRS for at least 1 year and who had 2 consecutive controlled LDL - C , non - HDL - C , and blood pressure within 6 months before enrollment ; 72 years .", "label": "", "metadata": {}, "score": "49.93705"}
{"text": "This between - group difference was driven mostly by gastrointestinal adverse events , particularly nausea .The most commonly reported adverse events ( nausea , fatigue , vomiting , headache , dizziness ) lasted a median of 14 days and were more likely to occur during the initial titration of CYCLOSET .", "label": "", "metadata": {}, "score": "50.165535"}
{"text": "Infusion Reactions .In the Rituxan RA pooled placebo - controlled studies , 32 % of Rituxan - treated patients experienced an adverse reaction during or within 24 hours following their first infusion , compared to 23 % of placebo - treated patients receiving their first infusion .", "label": "", "metadata": {}, "score": "50.22445"}
{"text": "Typically , these consultations lasted 10 - 15 minutes ( about 60 minutes in total ) in addition to the time taken for clinical profiling at baseline .", "label": "", "metadata": {}, "score": "50.23124"}
{"text": "Medication adherence was significantly increased in the intervention group than in the control group , for a \u03b2 - blocker in one study [ 14 ] , and for lipid - lowering drug in two studies [ 16 , 18 ] .", "label": "", "metadata": {}, "score": "50.236416"}
{"text": "In this study , we concluded that pharmacists have a beneficial role in the care of CHD patients , although the evidence supporting positive impacts on mortality and morbidity remains uncertain due to the unavailability of data in these areas .", "label": "", "metadata": {}, "score": "50.4048"}
{"text": "80 % ) , positive predictive value is low ( ?25%).3,22Furthermore , we could not determine er- rors of administration and other events that frequently occur in patients ' homes .", "label": "", "metadata": {}, "score": "50.41565"}
{"text": "Participants were consid- eredtohavecomplicatedhypertensioniftheyhadpriorevidence ofavasculardisorderorinsultindicatingpoorlycontrolledhy- pertension , includingmyocardialinfarction , coronaryheartdis- ease , stroke , heart failure , or renal insufficiency .Thus , the combined studies of 800 par- ticipantsformed2strataofcomplicated(232interventionand 303controlgrouppatients)anduncomplicated(134interven- tion and 131 control group patients ) hypertension .", "label": "", "metadata": {}, "score": "50.454727"}
{"text": "Adult outpatientswhoreceivecareatWishardHealthServicesarepre- dominatelywomen(66%)withamean(SD)ageof57(15)years .Most patients receive their prescription medications through state and local assistance plans at no cost .Patients were eligible for the heart failure study if they had adiagnosisofheartfailureconfirmedbytheirprimarycarephy- sician , were50yearsorolder , andregularlyusedatleast1car- diovascular medication for heart failure .", "label": "", "metadata": {}, "score": "50.530216"}
{"text": "Vomiting .Diarrhea .Constipation .Hypoglycemia .In the monotherapy trial , hypoglycemia was reported in 2 CYCLOSET - treated patients ( 3.7 % ) and 1 placebo - treated patient ( 1.3 % ) .", "label": "", "metadata": {}, "score": "50.7201"}
{"text": "Detailed safety data collection in Study 11 was limited to Grade 3 and 4 adverse reactions and serious adverse reactions .Infusion - related adverse reactions were defined by any of the following adverse events occurring during or within 24 hours of the start of infusion : nausea , pyrexia , chills , hypotension , vomiting , and dyspnea .", "label": "", "metadata": {}, "score": "50.756725"}
{"text": "Study endpoints .The primary endpoint was the percentage of participants who achieved their individualised blood pressure target according to national guidelines 6 during 26 weeks of follow - up ( using last recorded blood pressure for intention to treat analyses ) .", "label": "", "metadata": {}, "score": "50.972248"}
{"text": "The study group is given atorvastatin 80 mg / d\u00d72d before PCI while the control group receives usual care .After angiography , patients who are not undergoing PCI procedure will be excluded from the study as selection failure .", "label": "", "metadata": {}, "score": "51.051353"}
{"text": "Recruitment took place from July 2009 to December 2010 , with follow - up completed in July 2011 .Study design .This was an open label , two arm , randomised trial comparing an intensive blood pressure management strategy with usual care ( control ) .", "label": "", "metadata": {}, "score": "51.107155"}
{"text": "Focused medication counseling performed by the hospital study pharmacist , who identified and addressed barriers to medication adherence .A pocket medication card , a list of tips for remembering to take medications , and a pillbox were provided .", "label": "", "metadata": {}, "score": "51.167175"}
{"text": "Patients in the complicated stratum had heart failureorothercardiovascularcomplication . Computerpro- grams examined 1-year electronic record data to identify events classified as adverse drug events and preventable or potential adverse drug events .", "label": "", "metadata": {}, "score": "51.219048"}
{"text": "We included randomised controlled trials in patients undergoing major cardiac or vascular surgery who were allocated to a FFP group or a comparator ( no plasma or an active comparator , either clinical plasma ( any type ) or a plasma - derived blood product ) .", "label": "", "metadata": {}, "score": "51.3194"}
{"text": "Community Pharmacy Medicines Management Project Evaluation Team : The MEDMAN study : a randomized controlled trial of community pharmacy - led medicines management for patients with coronary heart disease .", "label": "", "metadata": {}, "score": "51.368156"}
{"text": "Cite this as : BMJ 2012;345:e7156 . Footnotes .We thank the study nurse coordinators for helping the general practitioner to participate in the study and the clinical trial research staff and data management staff at Baker IDI Heart and Diabetes Institute .", "label": "", "metadata": {}, "score": "51.411713"}
{"text": "There was no significant effect of pharmacist care on mortality , recurrent cardiac events or hospitalization of CHD patients .Significant positive effects of pharmacist care were shown on medication adherence in three studies , on blood pressure control in one study and on lipid management in one study .", "label": "", "metadata": {}, "score": "51.41182"}
{"text": "The second patient : .The second unblinded serious adverse event occurred in a 59 year old patient who , along with NASH , suffered from numerous other comorbid conditions for which she was taking several medications .", "label": "", "metadata": {}, "score": "51.523453"}
{"text": "PubMed View Article .Koshman SL , Charrois TL , Simpson SH , McAlister FA , Tsuyuki RT : Pharmacist care of patients with heart failure : a systematic review of randomized trials .", "label": "", "metadata": {}, "score": "51.56977"}
{"text": "Riskfactorsforadversedrugeventsamong older adults in the ambulatory setting .J Am Geriatr Soc .Hanlon JT , Weinberger M , Samsa GP , et al .A randomized , controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy .", "label": "", "metadata": {}, "score": "51.606796"}
{"text": "Risk of bias tools were applied as described in the Cochrane Handbook for Systematic Reviews of Intervention [ 13 ] .For each item , the quality characteristics of each study were rated as ( 1 ) low risk of bias ; ( 2 ) unclear ; and ( 3 ) high risk of bias .", "label": "", "metadata": {}, "score": "51.66851"}
{"text": "Scheduling of visits and up - titration of drug treatment was guided by the same computer program developed by Baker IDI to facilitate the initial risk profiling and management .", "label": "", "metadata": {}, "score": "51.70803"}
{"text": "This benefit was demonstrated in complex patients with CVD who were already receiving specialized care .The impact of this model on clinical outcomes requires further evaluation and should be a high priority given the burden of CVD in the population .", "label": "", "metadata": {}, "score": "51.72168"}
{"text": "Study entry .Eligible participants underwent baseline assessment , including determination of absolute cardiovascular risk .5 On the basis of this assessment , we identified target risk factor measures ( including blood pressure , lipid levels , exercise levels , smoking status , and body mass index ) for each participant according to national guidelines .", "label": "", "metadata": {}, "score": "51.727882"}
{"text": "The intervention was referral to a pharmacist clinic ; control was usual care from the cardiologist .The surrogate marker evaluated was the change in BP .", "label": "", "metadata": {}, "score": "51.958588"}
{"text": "No other events showed significant differences .bMiscellaneous category contains events numbering 0 or 1 in control and intervention groups .ARCH INTERN MED / VOL 169 ( NO . 8) , APR 27 , 2009 WWW.ARCHINTERNMED.COM 761 \u00a9 2009 American Medical Association .", "label": "", "metadata": {}, "score": "51.96419"}
{"text": "Patients in the complicated stratum had heart failure or other cardiovascular complication .Computer programs examined 1-year electronic record data to identify events classified as adverse drug events and preventable or potential adverse drug events .", "label": "", "metadata": {}, "score": "51.979717"}
{"text": "The incidence of these acute infusion reactions following the second infusion of Rituxan or placebo decreased to 9 % and 11 % , respectively .Acute infusion reactions required dose modification ( stopping , slowing , or interruption of the infusion ) in 10 % and 2 % of patients receiving rituximab or placebo , respectively , after the first course .", "label": "", "metadata": {}, "score": "52.070404"}
{"text": "Evidence of bleeding associated with nonsteroidal anti- inflammatory drugs including aspirin can be especially concerning and occurred in 5 and 2 patients in the con- trolandinterventiongroups , respectively;however , none of these events was severe .", "label": "", "metadata": {}, "score": "52.129364"}
{"text": "In patients receiving Rituxan as single - agent maintenance therapy following Rituxan plus chemotherapy , infections were reported more frequently compared to the observation arm ( 37 % vs. 22 % ) .", "label": "", "metadata": {}, "score": "52.157715"}
{"text": "However , both patients had confounding medical conditions which could have contributed to the cardiac adverse events , according to a medical review conducted by Intercept .", "label": "", "metadata": {}, "score": "52.18696"}
{"text": "e691 PubMed View Article .Ho PM , Spertus JA , Masoudi FA , Reid KJ , Peterson ED , Magid DJ , Krumholz HM , Rumsfeld JS : Impact of medication therapy discontinuation on mortality after myocardial infarction .", "label": "", "metadata": {}, "score": "52.26928"}
{"text": "The most frequent DRPs underlying interventions were unnecessary drug therapy , 36(24.2 % ) ; needs additional drug therapy , 34(22.8 % ) and noncompliance , 29(19.5 % ) .", "label": "", "metadata": {}, "score": "52.270397"}
{"text": "Gurwitz JH , Field TS , Harrold LR , et al .Incidence and preventability of adverse drug events among older persons in the ambulatory setting .", "label": "", "metadata": {}, "score": "52.394363"}
{"text": "Eur Heart J 2011 , 32 ( 23 ) : 2999 - 3054 .PubMed View Article .Menzin J , Wygant G , Hauch O , Jackel J , Friedman M : One - year costs of ischemic heart disease among patients with acute coronary syndromes : findings from a multi - employer claims database .", "label": "", "metadata": {}, "score": "52.47902"}
{"text": "Primary outcomes of interest for this study were mortality , cardiovascular events and hospitalizations .Mortality included both cardiovascular and non - cardiovascular mortality .Cardiovascular events included non - fatal myocardial infarction , stroke , and coronary and carotid revascularization .", "label": "", "metadata": {}, "score": "52.53334"}
{"text": "Secondary outcomes were medication adherence , blood pressure control , and lipid management .Results .Five RCTs ( 2568 patients ) were identified .The outcomes were mortality , cardiovascular events , and hospitalizations in one study ( 421 patients ) , medication adherence in five studies , blood pressure in two studies ( 1914 patients ) , and lipid management in three studies ( 932 patients ) .", "label": "", "metadata": {}, "score": "52.669483"}
{"text": "Vamos EP , Harris M , Millett C , Pape UJ , Khunti K , Curcin V , et al .Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes : retrospective cohort study .", "label": "", "metadata": {}, "score": "52.681686"}
{"text": "Of the 800 participants ( mean [ SD ] age , 59 [ 10 ] years ) , 484 ( 90.5 % ) and 258 ( 97.4 % ) participants remained in the complicated and uncomplicated strata , respectively , at 12 months .", "label": "", "metadata": {}, "score": "52.84264"}
{"text": "The incidence of serious infections was 11 % in the Rituxan - treated patients and 10 % in the cyclophosphamide treated patients , with rates of approximately 25 and 28 per 100 patient - years , respectively .", "label": "", "metadata": {}, "score": "53.05728"}
{"text": "Due to the unavailability of data and the limited number of the studies , we could not carry out a quantitative meta - analysis .However , through qualitative analysis of the available data , we were able to evaluate the impact of pharmacist care on patients with CHD .", "label": "", "metadata": {}, "score": "53.077785"}
{"text": "A re- search assistant then randomly assigned patients to either an intervention or control group using a computer randomiza- tion protocol .In the heart failure study , there were 314 par- ticipants ( 122 in the intervention group and 192 in the con- trol group ) .", "label": "", "metadata": {}, "score": "53.25467"}
{"text": "The first of the unblinded serious adverse events occurred in a 73 year old patient who , along with NASH and type 2 diabetes , suffered from a number of other comorbid conditions for which she was taking numerous medications .", "label": "", "metadata": {}, "score": "53.27303"}
{"text": "PubMed View Article .Rublee DA , Chen SY , Mardekian J , Wu N , Rao P , Boulanger L : Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy .", "label": "", "metadata": {}, "score": "53.53074"}
{"text": "In the complicated stratum , there were 0.14 ( 0.5 ) MEs perparticipantinthecontrolgroupand0.10(0.4)inthe intervention group ( difference not significant ) .Risk ratios comparing control and intervention effects by group are listed in Table 5 . Theseeffectsoftheinterventionwerecon- sistent within complicated and uncomplicated strata .", "label": "", "metadata": {}, "score": "53.533318"}
{"text": "PubMed View Article .Kumbhani DJ , Steg PG , Cannon CP , Eagle KA , Smith SC Jr , Hoffman E , Goto S , Ohman EM , Bhatt DL : Adherence to secondary prevention medications and four - year outcomes in outpatients with atherosclerosis .", "label": "", "metadata": {}, "score": "53.53926"}
{"text": "Julius S , Weber MA , Kjeldsen SE , McInnes GT , Zanchetti A , Brunner HR , et al .The Valsartan Antihypertensive Long - Term Use Evaluation ( VALUE ) trial : outcomes in patients receiving monotherapy .", "label": "", "metadata": {}, "score": "53.68911"}
{"text": "Three studies reported the number of patients who achieved low - density lipoprotein cholesterol ( LDL - C ) control target levels [ 16 - 18 ] .", "label": "", "metadata": {}, "score": "53.752186"}
{"text": "The rate of dizziness ( 0.07 v 0.03 adverse events / participant ) and oedema ( predominantly peripheral oedema , 0.06 v 0.03 adverse events / participants ) was highest in the intervention group overall , and most common in the combination arm .", "label": "", "metadata": {}, "score": "53.850018"}
{"text": "Whilethesefindingsweretheresultofapooled estimate involving 2 studies , the effects were consistent within individual studies .Most of the events ( 90 % ) de-rived from individuals with complicated cardiovascular disease such as heart failure who had more complicated drug regimens .", "label": "", "metadata": {}, "score": "53.89292"}
{"text": "The hazard ratio comparing CYCLOSET to placebo for the timeto - first occurrence of the prespecified composite cardiovascular endpoint was 0.58 ( two - sided 95 % confidence interval , 0.35 - 0.96 ) .", "label": "", "metadata": {}, "score": "53.949806"}
{"text": "Further adequately powered studies of FFP , or comparable pro - haemostatic agents , are required to assess whether larger reductions in prothrombin time translate into clinical benefits .", "label": "", "metadata": {}, "score": "53.98021"}
{"text": "Other Grade 3 or 4 adverse reactions occurring more frequently among patients receiving R - CHOP were viral infection ( Study 8) , neutropenia ( Studies 8 and 9 ) , and anemia ( Study 9 ) .", "label": "", "metadata": {}, "score": "54.490463"}
{"text": "Secondary prevention is important because cardiovascular events occur at a high rate after an acute vascular event [ 2 ] .For example , about one fifth of patients were rehospitalized for ischemic heart disease or died within a year after the first acute coronary syndrome ( ACS ) [ 3 ] .", "label": "", "metadata": {}, "score": "54.503803"}
{"text": "Results : Ofthe800participants(mean[SD]age,59[10 ] years ) , 484 ( 90.5 % ) and 258 ( 97.4 % ) participants re- mainedinthecomplicatedanduncomplicatedstrata , re- spectively , at 12 months .", "label": "", "metadata": {}, "score": "54.548782"}
{"text": "Participationineitherstudyrequiredthat thepatientplannedtoreceiveallprimarycareatthestudycen- ter and their prescription drugs at a Wishard pharmacy .The heart failure study was conducted from February 2001 to No- vember2004,andthehypertensionstudywasconductedfrom January 2002 to May 2005 .", "label": "", "metadata": {}, "score": "54.566593"}
{"text": "The study investigators and sponsor jointly assessed study data .All the investigators received remuneration from Baker IDI for the research component of clinical study activities .", "label": "", "metadata": {}, "score": "54.57795"}
{"text": "We then randomised into the study those who did not achieve their prespecified blood pressure target within this run - in period or were not specifically withdrawn or lost to follow - up ( blinded allocation ) .", "label": "", "metadata": {}, "score": "54.579597"}
{"text": "Setting General practices throughout Australia , except Northern Territory , 2009 - 11 .Participants Of 2185 patients from 119 general practices who were eligible for drug treatment for hypertension according to national guidelines 416 ( 19.0 % ) achieved their individual blood pressure target during a 28 day run - in period of monotherapy .", "label": "", "metadata": {}, "score": "54.639557"}
{"text": "View Article .Faulkner MA , Wadibia EC , Lucas BD , Hilleman DE : Impact of pharmacy counseling on compliance and effectiveness of combination lipid - lowering therapy in patients undergoing coronary artery revascularization : a randomized , controlled trial .", "label": "", "metadata": {}, "score": "54.795444"}
{"text": "In the uncomplicated stratum , there were 14 events in the control group and 7 in the intervention group .The overall mean numbers of ADEs and MEs per participant were 0.07 ( 0.30 ) and 0.03 ( 0.20 ) for control andinterventiongroups , respectively(differencenotsig- nificant ) .", "label": "", "metadata": {}, "score": "54.807568"}
{"text": "Figures in appendix II in the supplementary file show the ( complex ) pattern of prescribing in the usual care group and the composite treatment groups comprising the intervention group .", "label": "", "metadata": {}, "score": "55.014755"}
{"text": "Theinterventionwassimilarinbothstudiesexceptfor itsdurationandfollow - up .Intheheartfailurestudy , interven- tion participants received the intervention for 9 months with a3-monthpostinterventionfollow - upperiod . Inthehyperten-sionstudy , theinterventionlastedfor12monthswitha6-month postintervention follow - up .", "label": "", "metadata": {}, "score": "55.023037"}
{"text": "In the active - controlled , double - blind study , subsequent courses of Rituxan were allowed for patients experiencing a relapse of disease .The limited data preclude any conclusions regarding the safety of subsequent courses of Rituxan with GPA and MPA [ See DOSAGE AND ADMINISTRATION , and WARNINGS AND PRECAUTIONS ] .", "label": "", "metadata": {}, "score": "55.24582"}
{"text": "In patients who did not have prolonged neutropenia , the frequency of late - onset neutropenia was 14.8 % of 209 patients who received R - FC and 4.3 % of 230 patients who received FC .", "label": "", "metadata": {}, "score": "55.27118"}
{"text": "Weber MA , Julius S , Kjeldsen SE , Brunner HR , Ekman S , Hansson L , et al .Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial .", "label": "", "metadata": {}, "score": "55.386448"}
{"text": "Kjeldsen SE , Jamerson KA , Bakris GL , Pitt B , Dahlof B , Velazquez EJ , et al .Predictors of blood pressure response to intensified and fixed combination treatment of hypertension : the ACCOMPLISH study .", "label": "", "metadata": {}, "score": "55.396076"}
{"text": "Medication adherence .All the five studies reported about medication adherence .Methods of medication adherence assessment and main outcomes of each study are shown in Table 2 .", "label": "", "metadata": {}, "score": "55.42662"}
{"text": "The community pharmacist monitored for problems with adherence and communicated issues back to the patient and the patient 's care team .Every 6 weeks .", "label": "", "metadata": {}, "score": "55.643753"}
{"text": "LeapeLL , CullenDJ , ClappMD , etal .Pharmacistparticipationonphysicianrounds and adverse drug events in the intensive care unit .JAMA .Schnipper JL , Kirwin JL , Cotugno MC , et al .", "label": "", "metadata": {}, "score": "56.00283"}
{"text": "PubMed View Article .Calvert SB , Kramer JM , Anstrom KJ , Kaltenbach LA , Stafford JA , Allen LaPointe NM : Patient - focused intervention to improve long - term adherence to evidence - based medications : a randomized trial .", "label": "", "metadata": {}, "score": "56.122196"}
{"text": "14 By necessity , this pragmatic study used an open label design ( with no blinding of treatment pathways or blood pressure measurements possible ) with scheduled visits that varied according to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in Australia .", "label": "", "metadata": {}, "score": "56.207115"}
{"text": "Morris AB , Li J , Kroenke K , Bruner - England TE , Young JM , Murray MD .Factors associated with drug adherence and blood pressure control in patients with hypertension .", "label": "", "metadata": {}, "score": "56.213398"}
{"text": "Rates of serious infection remained stable in patients receiving subsequent courses .In 185 Rituxan - treated RA patients with active disease , subsequent treatment with a biologic DMARD , the majority of which were TNF antagonists , did not appear to increase the rate of serious infection .", "label": "", "metadata": {}, "score": "56.356277"}
{"text": "Stewart S , Carrington MJ , Marwick T , Davidson PM , Macdonald P , Horowitz J , et al .Impact of home versus clinic based management of chronic heart failure : the WHICH ?", "label": "", "metadata": {}, "score": "56.444862"}
{"text": "SIDE EFFECTS .Clinical Trials Experience .Because clinical trials are conducted under widely varying conditions , the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial , and may not reflect the rates actually observed in clinical practice .", "label": "", "metadata": {}, "score": "56.558105"}
{"text": "Although there are no reports on the benefits of pharmacist intervention in mortality and morbidity of CHD , this review details the potential benefits of pharmacists on CHD care processes .", "label": "", "metadata": {}, "score": "56.6438"}
{"text": "PubMed View Article .Gehi AK , Ali S , Na B , Whooley MA : Self - reported medication adherence and cardiovascular events in patients with stable coronary heart disease : the heart and soul study .", "label": "", "metadata": {}, "score": "56.645782"}
{"text": "The last visit will be at 6 months after PCI .Patients data such as troponin , CK - MB , Scr , CCR , ALT , AST before and after procedure will be recorded .", "label": "", "metadata": {}, "score": "56.80522"}
{"text": "PubMed View Article .Santschi V , Chiolero A , Burnand B , Colosimo AL , Paradis G : Impact of pharmacist care in the management of cardiovascular disease risk factors : a systematic review and meta - analysis of randomized trials .", "label": "", "metadata": {}, "score": "56.856308"}
{"text": "Secondary outcomes were medication adherence , blood pressure control , and lipid management .Publications were excluded if they were not randomized , did not have adequate description of the pharmacist 's intervention , did not directly apply to patients with CHD , were not conducted on patients all with CHD , or if they did not report the targeted outcomes .", "label": "", "metadata": {}, "score": "56.925995"}
{"text": "Call your doctor for medical advice about side effects .You may report side effects to FDA at 1 - 800-FDA-1088 .What is Patient Information in Detail ?", "label": "", "metadata": {}, "score": "57.05084"}
{"text": "Consultations of therapy , medication compliance , lifestyle and social support were provided by the community pharmacist and recommendations were recorded and sent to the GP , who returned annotated copies to the pharmacists .", "label": "", "metadata": {}, "score": "57.206512"}
{"text": "Thus , even patients in the control group also received intensive pharmacist care before the study .Unfortunately , we could not find any other study comparing the pharmacist care to the ' real ' usual care for mortality , cardiac events and hospitalizations of patients with CHD .", "label": "", "metadata": {}, "score": "57.25048"}
{"text": "Chobanian AV , Bakris GL , Black HR , Cushman WC , Green LA , Izzo JL Jr , et al .The seventh report of the Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure : the JNC 7 report .", "label": "", "metadata": {}, "score": "57.25817"}
{"text": "None of the serious adverse events grouped by System - Organ - Class occurred more than 0.3 percentage points higher with CYCLOSET than with placebo .", "label": "", "metadata": {}, "score": "57.267906"}
{"text": "The goal is to set up an optimized protocol for peri - PCI statin treatment in Chinese CHD patients .Safety will also be observed .", "label": "", "metadata": {}, "score": "57.462646"}
{"text": "2 Epidemiological studies suggest a relation between raised blood pressure and increased risk of cardiovascular events .Considering the recent debate on whether more stringent blood pressure targets fail to provide cardioprotection and perhaps even confer harm at blood pressure levels approaching 110/75 mm Hg 8 it is likely that more stringent blood pressure targets will be subject to further consideration .", "label": "", "metadata": {}, "score": "57.53487"}
{"text": "There were no reported adverse events due to FFP transfusion .Overall the evidence for the safety and efficacy of prophylactic FFP for cardiac surgery is insufficient .", "label": "", "metadata": {}, "score": "57.587868"}
{"text": "Authors ' conclusions : .This review has found no evidence to support the prophylactic administration of FFP to patients without coagulopathy undergoing elective cardiac surgery .", "label": "", "metadata": {}, "score": "57.667973"}
{"text": "Usual care .We explicitly acknowledged that this was an enhanced form of usual care given that the participants had already been subject to clinical profiling and had an identified blood pressure target and their doctors potentially had knowledge of the intervention ( with the inherent problem of contamination ) .", "label": "", "metadata": {}, "score": "57.738556"}
{"text": "Infusion reactions typically occurred within 30 to 120 minutes of beginning the first infusion and resolved with slowing or interruption of the Rituxan infusion and with supportive care ( diphenhydramine , acetaminophen , and intravenous saline ) .", "label": "", "metadata": {}, "score": "57.90416"}
{"text": "The Rituxan group did not receive additional therapy to maintain remission .The primary analysis was at the end of the 6 month remission induction period and the safety results for this period are described below .", "label": "", "metadata": {}, "score": "57.944786"}
{"text": "However , it is likely that much of the intervention 's effect on reducing the risk of Table 3 .Number and Percentage of Events by Complication and Treatment Group Status Study Group Events , No .", "label": "", "metadata": {}, "score": "57.959053"}
{"text": "\" This technique will give us additional information to use in selecting patients that need aggressive treatment , \" he said . \"Increasing Carotid Plaque Echolucency Predicts Cardiovascular Events in High Risk Patients .", "label": "", "metadata": {}, "score": "58.045853"}
{"text": "Prolonged neutropenia is defined as Grade 3 - 4 neutropenia that has not resolved between 24 and 42 days after the last dose of study treatment .", "label": "", "metadata": {}, "score": "58.074524"}
{"text": "Study participant flowchart .Table 2 .Patient Characteristics Stratified by Complication and Interventiona Characteristic Age , mean ( SD ) , y Education , mean ( SD ) , y Women , No .", "label": "", "metadata": {}, "score": "58.19124"}
{"text": "In previous studies of NASH in patients without diabetes , cardiovascular events were reported .Of the 10 cardiovascular serious adverse events reported in the FLINT study , none were considered probably or definitely related to OCA .", "label": "", "metadata": {}, "score": "58.237434"}
{"text": "Secondary endpoints also included the type and rate of adverse events potentially attributable to antihypertensive treatment , and serious adverse events including all cause mortality and fatal and non - fatal cardiovascular events - for example , acute myocardial infarction , stroke , and heart failure .", "label": "", "metadata": {}, "score": "58.26611"}
{"text": "Additionally , the bibliographies of all relevant articles were reviewed .Study selection .Two authors ( HX and HC ) independently screened the citations from the literature search to determine eligibility ( Figure 1 ) .", "label": "", "metadata": {}, "score": "58.326736"}
{"text": "The population included 1180 patients with low grade or follicular lymphoma , 927 patients with DLBCL , and 676 patients with CLL .Most NHL patients received Rituxan as an infusion of 375 mg / m\u00b2 per infusion , given as a single agent weekly for up to 8 doses , in combination with chemotherapy for up to 8 doses , or following chemotherapy for up to 16 doses .", "label": "", "metadata": {}, "score": "58.3432"}
{"text": "AspdenP , WolcottJW , BootmanJL , CronenwettLR.PreventingMedicalErrors .Washington , DC : National Academies Press ; 2006 .Shaughnessy AF , Nickel RO .Prescription - writing patterns and errors in a family medicine residency program .", "label": "", "metadata": {}, "score": "58.49091"}
{"text": "Wing LM , Reid CM , Ryan P , Beilin LJ , Brown MA , Jennings GL , et al .A comparison of outcomes with angiotensin - converting - enzyme inhibitors and diuretics for hypertension in the elderly .", "label": "", "metadata": {}, "score": "58.748306"}
{"text": "Study power .We largely met the study targets for overall recruitment and number of participants entering the run - in phase .Based on the combination of a strong potential for interventional contamination , balanced against the need to establish clinically significant differences between the two groups , the study was initially powered to detect a minimum absolute difference of 7 % between the groups for the primary endpoint .", "label": "", "metadata": {}, "score": "58.754196"}
{"text": "Franklin SS , Thijs L , Hansen TW , Li Y , Boggia J , Kikuya M , et al .Significance of white - coat hypertension in older persons with isolated systolic hypertension : a meta - analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population .", "label": "", "metadata": {}, "score": "58.90498"}
{"text": "Of those , ultrasound determined that 574 patients had carotid artery disease , as determined by the amount of plaque built up in the two vessels that supply blood to the head and neck .", "label": "", "metadata": {}, "score": "58.980145"}
{"text": "As such , these data may prompt a re - evaluation of blood pressure targets to reflect real world limitations for doctors managing hypertension in the busy and often complex primary care setting .", "label": "", "metadata": {}, "score": "58.99475"}
{"text": "Am J Health Syst Pharm .Thomsen LA , Winterstein AG , Sondergaard B , Haugbolle LS , Melander A. Sys- tematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care .", "label": "", "metadata": {}, "score": "58.99888"}
{"text": "There were no reported adverse events attributable to FFP transfusion , although there was a significant increase in the number of patients requiring red cell transfusion who were randomised to FFP .", "label": "", "metadata": {}, "score": "59.016464"}
{"text": "The positive impact of CPS ( or pharmaceutical care services ) on clinical , economic and humanistic outcomes has been demonstrated in numerous studies in the North America and United Kingdom ( UK ) .", "label": "", "metadata": {}, "score": "59.036713"}
{"text": "The data below reflect exposure to Rituxan in combination with fludarabine and cyclophosphamide in 676 patients with CLL in Study 11 or Study 12 [ See Clinical Studies ] .", "label": "", "metadata": {}, "score": "59.04472"}
{"text": "PubMed View Article .Olson KL , Delate T , Rasmussen J , Humphries TL , Merenich JA , Clinical Pharmacy Cardiac Risk Service Study G : Outcomes of patients discharged from pharmacy - managed cardiovascular disease management .", "label": "", "metadata": {}, "score": "59.08846"}
{"text": "Yang Q , Cogswell ME , Flanders WD , Hong Y , Zhang Z , Loustalot F , et al .Trends in cardiovascular health metrics and associations with all - cause and CVD mortality among US adults .", "label": "", "metadata": {}, "score": "59.297916"}
{"text": "Physicians and healthcare providers should make necessary efforts to engage the patient 's active participation in prescribed medical regimens and lifestyle changes to improve the prognosis of CHD .", "label": "", "metadata": {}, "score": "59.800613"}
{"text": "FieldTS , GilmanBH , SubramanianS , FullerJC , BatesDW , GurwitzJH.Thecosts associated with adverse drug events among older adults in ambulatory setting .Med Care .", "label": "", "metadata": {}, "score": "59.850082"}
{"text": "J Am Med Inform Assoc .2003;10(4):389 - 398 .Seger A , Gandhi T , Hope C , et al .Development of a computerized adverse drug event ( ADE ) monitor in the outpatient setting .", "label": "", "metadata": {}, "score": "59.875828"}
{"text": "However , it shows that the pharmacist can help to improve medication adherence , blood pressure and lipid control .This review did not confirm the benefits of pharmacist intervention on mortality and morbidity of CHD .", "label": "", "metadata": {}, "score": "59.939705"}
{"text": "Usingcomputerizeddatatoidentifyadverse drug events in outpatients .J Am Med Inform Assoc .2001;8(3):254 - 266 .GandhiTK , WeingartSN , BorusJ , etal .Adversedrugeventsinambulatorycare .", "label": "", "metadata": {}, "score": "59.971607"}
{"text": "See WARNINGS AND PRECAUTIONS , Clinical Studies ] .Infections .Serious infections ( NCI CTCAE Grade 3 or 4 ) , including sepsis , occurred in less than 5 % of patients with NHL in the single - arm studies .", "label": "", "metadata": {}, "score": "59.994595"}
{"text": "In studies of monotherapy , Rituxan - induced B - cell depletion occurred in 70 % to 80 % of patients with NHL .Decreased IgM and IgG serum levels occurred in 14 % of these patients .", "label": "", "metadata": {}, "score": "60.07763"}
{"text": "Retreatment in Patients with RA .Most of the patients who received additional courses did so 24 weeks or more after the previous course and none were retreated sooner than 16 weeks .", "label": "", "metadata": {}, "score": "60.133305"}
{"text": "Patients who had FFP received significantly more red blood cells , suggesting that FFP may not be effective in this setting ( moderate quality evidence ) .", "label": "", "metadata": {}, "score": "60.140144"}
{"text": "While we know the FLINT study was stopped early because of OCA 's benefit in NASH patients , detailed data have not yet been disclosed .", "label": "", "metadata": {}, "score": "60.21489"}
{"text": "Feldman RD , Zou GY , Vandervoort MK , Wong CJ , Nelson SA , Feagan BG .A simplified approach to the treatment of uncomplicated hypertension : a cluster randomized , controlled trial .", "label": "", "metadata": {}, "score": "60.269054"}
{"text": "Over the subsequent month , during which time the patient remained hospitalized in the ICU , she experienced cardiogenic shock , respiratory failure , deteriorating kidney function and a number of other complications .", "label": "", "metadata": {}, "score": "60.281662"}
{"text": "Every 6 weeks .Methodological quality of included studies .The studies were of variable methodological quality .Three studies provided evidence of adequate random sequence generation [ 14 , 16 , 17 ] and only two studies reported adequate concealment [ 14 , 15 ] .", "label": "", "metadata": {}, "score": "60.30936"}
{"text": "In the 52-week CYCLOSET safety trial , 11.5 % of CYCLOSET - treated women compared to 3.6 % of placebo - treated women reported vomiting .", "label": "", "metadata": {}, "score": "60.666748"}
{"text": "Medication errors were the subset of ADE events involvingMEs;namely , preventableADEsandpotentialADEs .Risk ratios for the counts of ADEs or MEs were calculated for intervention and control participants using Poisson regres- sion models .", "label": "", "metadata": {}, "score": "60.715683"}
{"text": "The GIANT trial evaluated the clinical impact of CYP2C19 genetic profiling and compliance to an adjusted thienopyridine treatment .The primary endpoint was a composite of death , myocardial infarction , and stent thrombosis after one year in slow responder patients with appropriate therapy after genotyping , compared to non - slow responders .", "label": "", "metadata": {}, "score": "61.078575"}
{"text": "Data extraction and risk of bias assessment .Data extraction was independently performed by 2 authors ( HX and YH ) using a standardized data extraction form .", "label": "", "metadata": {}, "score": "61.211678"}
{"text": "Introduction .Although hypertension is a readily detectable and modifiable condition it is responsible for more deaths worldwide than any other cardiovascular risk factor , including tobacco use , obesity , and lipid disorders . 1", "label": "", "metadata": {}, "score": "61.21432"}
{"text": "MEASUREMENTS Data on ADEs and MEs were collected for 12 months using a program developed for a separate study.22,23This program ex- amined coded and text electronic health record data to identify triggers suggestive of selected ADEs and MEs in outpatients .", "label": "", "metadata": {}, "score": "61.352154"}
{"text": "Among all exposed patients , adverse reactions reported in greater than 10 % of patients include infusion - related reactions , upper respiratory tract infection , nasopharyngitis , urinary tract infection , and bronchitis .", "label": "", "metadata": {}, "score": "61.374535"}
{"text": "Law MR , Morris JK , Wald NJ .Use of blood pressure lowering drugs in the prevention of cardiovascular disease : meta - analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies .", "label": "", "metadata": {}, "score": "61.389618"}
{"text": "Circulation 2011 , 124 ( 22 ) : 2458 - 2473 .PubMed View Article .Rasmussen JN , Chong A , Alter DA : Relationship between adherence to evidence - based pharmacotherapy and long - term mortality after acute myocardial infarction .", "label": "", "metadata": {}, "score": "61.511536"}
{"text": "J Gen Intern Med .Bates DW , Evans RS , Murff H , Stetson PD , Pizziferri L , Hripcsak G. Detecting adverse events using information technology .", "label": "", "metadata": {}, "score": "61.584812"}
{"text": "Theroleofmanagedcarepharmacyin reducing medication errors .J Manag Care Pharm .Institute for Safe Medication Practices .Accessed December 4 , 2008 .Thomas EJ , Petersen LA .", "label": "", "metadata": {}, "score": "61.755295"}
{"text": "McDonaldCJ , OverhageJM , TierneyWM , etal .TheRegenstriefMedicalRecord System : a quarter century experience .Int J Med Inform .MurrayMD , SmithFE , FoxJ , etal .", "label": "", "metadata": {}, "score": "61.805244"}
{"text": "Feuerstein appreciates your feedback ; click here to send him an email .Clinical Trials Experience in Lymphoid Malignancies .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice .", "label": "", "metadata": {}, "score": "61.860634"}
{"text": "It is important to note that the results showed that vulnerable plaque in the carotid artery was not only an indicator of increased risk of stroke downstream from the carotid artery , but also was associated with disease progression elsewhere in the cardiovascular system .", "label": "", "metadata": {}, "score": "62.035965"}
{"text": "Clinical Trials Experience in Rheumatoid Arthritis .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice .", "label": "", "metadata": {}, "score": "62.32184"}
{"text": "The nurse adjudicator was trained usingmethodssimilartothoseusedinpreviousstudiesthathad goodinterrateragreement ( ?valuesof0.815and0.894)andhad more than 15 years of experience in quality assurance includ- ing medication safety research .ARCH INTERN MED / VOL 169 ( NO . 8) , APR 27 , 2009WWW .", "label": "", "metadata": {}, "score": "62.37458"}
{"text": "Fur - thermore , 60.4 % ( 102/169 ) of inappropriate prescriptions pos - sessed the potential for moderate or severe clinical consequences , as evaluated by a panel of two clinical pharmacologists and one nephrolo - gist .", "label": "", "metadata": {}, "score": "62.394653"}
{"text": "MI : .Myocardial infarction .PCI : .Percutaneous coronary intervention .PTCA : .Percutaneous transluminal coronary angioplasty .RCT : .Randomized controlled trial .", "label": "", "metadata": {}, "score": "62.41081"}
{"text": "INDEPENDENT VARIABLES Data on age , sex , race , years of formal education , marital sta- tus , household income adequacy , and insurance were col- lected at the baseline interview .", "label": "", "metadata": {}, "score": "62.81767"}
{"text": "J Am Geriatr Soc .Kroenke K , Wyrwich KW , Tierney WM , Babu AN , Wolinsky FD .Physician-estimateddiseaseseverityinpatientswithchronicheartorlungdisease : across- sectional analysis .", "label": "", "metadata": {}, "score": "62.901703"}
{"text": "MurrayMD , YoungJM , MorrowDG , etal .Methodologyofanongoing , random- ized , controlled trial to improve drug use for elderly patients with chronic heart failure .", "label": "", "metadata": {}, "score": "62.9584"}
{"text": "Using an ELISA assay , anti - human anti - chimeric antibody ( HACA ) was detected in 4 of 356 ( 1.1 % ) patients with low - grade or follicular NHL receiving single - agent Rituxan .", "label": "", "metadata": {}, "score": "62.99694"}
{"text": "Page 6 . such events in this study derived from pharmacist drug monitoring and communicating with physicians and nurses .Pharmacists regularly communicated with physi- cians and nurses concerning patient - reported symp- toms , drug - related problems including ADEs and MEs , and changes in important drug - monitoring parameters such as laboratory results affected by drugs .", "label": "", "metadata": {}, "score": "63.00891"}
{"text": "This table reflects experience in 99 GPA and MPA patients treated with Rituxan , with a total of 47.6 patient - years of observation and 98 GPA and MPA patients treated with cyclophosphamide , with a total of 47.0 patient - years of observation .", "label": "", "metadata": {}, "score": "63.099564"}
{"text": "The study statistician ( on behalf of the clinical safety and efficacy committee ) independently analysed the data according to a prospectively designed statistical analysis plan .", "label": "", "metadata": {}, "score": "63.16055"}
{"text": "DLBCL .Detailed safety data collection in these studies was primarily limited to Grade 3 and 4 adverse reactions and serious adverse reactions .In Study 8 , a review of cardiac toxicity determined that supraventricular arrhythmias or tachycardia accounted for most of the difference in cardiac disorders ( 4.5 % for R - CHOP vs. 1.0 % for CHOP ) .", "label": "", "metadata": {}, "score": "63.189754"}
{"text": "Participants .Study participants were recruited by 260 general practitioners from 119 general practices distributed throughout every state and territory of Australia except the sparsely populated Northern Territory .", "label": "", "metadata": {}, "score": "63.36898"}
{"text": "Hallucinations and mental confusion including delusions have been reported with bromocriptine .Fibrotic -Related Complications .Fibrotic complications , including cases of retroperitoneal fibrosis , pulmonary fibrosis , pleural effusion , pleural thickening , pericarditis and pericardial effusions have been reported .", "label": "", "metadata": {}, "score": "63.48955"}
{"text": "The CYCLOSET safety trial was a 52-week , placebo - controlled study that included patients treated only with diet therapy or with other anti - diabetic medications .", "label": "", "metadata": {}, "score": "63.50966"}
{"text": "XY supervised the study and revised the manuscript .All authors approved the final manuscript .Authors ' Affiliations .Department of Cardiovascular Medicine , First Affiliated Hospital , Zhejiang Chinese Medical University .", "label": "", "metadata": {}, "score": "63.71764"}
{"text": "5 d Anticonvulsants Carbamazepine concentration not measured Dizziness Phenytoin and nystagmus Infection / Antimicrobials Oral candidiasis Vaginal candidiasis Oral metronidazole or vancomycin Topical steroid for rash Urticaria Clostridium difficile colitis Glucose / Diabetes Metformin toxic effects Glucocorticoid - associated glucose intolerance Hypoglycemia , blood glucose level ?", "label": "", "metadata": {}, "score": "63.851677"}
{"text": "This study was conducted at VieCuri Medical Centre in Venlo , Netherlands .Patient demographics and renal function data were col - lected , and dosage adjustment needs were assessed via the pharmacy - supported discharge counseling ser - vice .", "label": "", "metadata": {}, "score": "63.854893"}
{"text": "On the conference call and webcast , management will ... quarter and business outlook .Abstract .Background .Secondary prevention is important for reducing both mortality and morbidity of patients with coronary heart disease ( CHD ) .", "label": "", "metadata": {}, "score": "63.901794"}
{"text": "Bates DW , Boyle DL , Vander Vliet MB , Schneider J , Leape L. Relationship be- tween medication errors and adverse drug events .J Gen Intern Med .", "label": "", "metadata": {}, "score": "63.97324"}
{"text": "The contributions from pharmacists in CHD secondary prevention have not been systematically reviewed so far , and hence we have carried out this study to evaluate the role of pharmacist care on mortality , morbidity , and the management of CHD .", "label": "", "metadata": {}, "score": "64.031334"}
{"text": "This review has been carried out to evaluate the role of pharmacist care on mortality , morbidity , and the CHD management .Methods .The PubMed , MEDLINE , EMBASE , Web of Science and Cochrane Central Register of Controlled Trials databases were searched for randomized controlled trials ( RCTs ) to evaluate the impact of pharmacist care interventions on patients with CHD ( in both community and hospital settings ) .", "label": "", "metadata": {}, "score": "64.077194"}
{"text": "The role of clinical pharmacists in comprehensive outpatient CVD management has not been evaluated .The objective of this pilot study was to evaluate the impact of a clinical pharmacist added to cardiologist care on blood pressure ( BP ) , a key surrogate marker of CVD , in outpatients with CVD compared to cardiologist care alone .", "label": "", "metadata": {}, "score": "64.14839"}
{"text": "Because these reactions are reported voluntarily from a population of uncertain size , it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "64.325165"}
{"text": "J Am Coll Cardiol 2012 ; 60 : 1239 -48 .Log in or register : .Download this article to citation manager .Stewart Simon , Carrington Melinda J , Swemmer Carla H , Anderson Craig , Kurstjens Nicol P , Amerena John et al .", "label": "", "metadata": {}, "score": "64.550285"}
{"text": "Evidence of a personally signed and dated informed consent document .Patients presenting with ST - segment elevation acute myocardial infarction ( STEMI ) or high risk NSTE - ACS , warranting emergency coronary angiography : .", "label": "", "metadata": {}, "score": "64.5611"}
{"text": "Arch Intern Med .Kaboli PJ , Hoth AB , McClimon BJ , Schnipper JL .Clinical pharmacists and inpa- tient medical care : a systematic review .", "label": "", "metadata": {}, "score": "64.58732"}
{"text": "We excluded studies of plasmapheresis and plasma exchange .Data collection and analysis : .Two authors screened all electronically derived citations and abstracts of papers identified by the review search strategy .", "label": "", "metadata": {}, "score": "64.66098"}
{"text": "Reiter and his team used ultrasound images and computer - assisted gray scale median ( GSM ) measurements to determine the density of the plaque lining the carotid arteries .", "label": "", "metadata": {}, "score": "64.740654"}
{"text": "Drug dosage adjust - ments according to renal function at hos - pital discharge .Ann Pharmacother .SAN FRANCISCO , CA October 31 , 2013", "label": "", "metadata": {}, "score": "64.843475"}
{"text": "All authors had full access to all the data and read and approved the final version of the manuscript .All authors had final responsibility for the decision to submit the manuscript for publication .", "label": "", "metadata": {}, "score": "64.95514"}
{"text": "Ernst FR , Grizzle AJ .Drug - related morbidity and mortality : updating the cost- of - illness model .J Am Pharm Assoc ( Wash ) .", "label": "", "metadata": {}, "score": "65.06424"}
{"text": "We also searched the references of all identified trials and relevant review articles .We did not limit the searches by language or publication status .", "label": "", "metadata": {}, "score": "65.125244"}
{"text": "The cause of syncope is not known in all cases [ See WARNINGS AND PRECAUTIONS ] .In this trial , electrocardiograms were not available at the time of these events , but an assessment of routine electrocardiograms obtained during the course of the trial did not identify arrhythmias or QTc interval prolongation among the CYCLOSET - treated patients reporting syncope .", "label": "", "metadata": {}, "score": "65.17419"}
{"text": "However , anim- portantpartoftheinterventionintheheartfailurestudy was to remind physicians of the importance of prescrib- ing ACE inhibitors to patients with heart failure . There-fore , it would be expected that prescriptions for these drugs in ACE inhibitor - na\u00efve patients would lead to a greaterriskofallergies .", "label": "", "metadata": {}, "score": "65.24017"}
{"text": "The mean baseline body mass index was 32 kg / m\u00b2 .The mean duration of diabetes at baseline was 8 years and the mean baseline HbA1c was 7.0 % with a mean baseline fasting plasma glucose of 142 mg / dL. Forty - seven percent of the CYCLOSET - treated patients and 32 % of the placebo - treated patients prematurely discontinued treatment .", "label": "", "metadata": {}, "score": "65.266556"}
{"text": "Medication dispensing errors and potential adverse drug events before and after implementing bar code technology in the pharmacy .Ann Intern Med .Miller DK , Malmstrom TK , Joshi S , Andresen EM , Morley JE , Wolinsky FD .", "label": "", "metadata": {}, "score": "65.57933"}
{"text": "Rupp MT , DeYoung M , Schondelmeyer SW .Prescribing problems and pharma- cist interventions in community practice .Med Care .Flynn EA , Barker KN , Gibson JT , Pearson RE , Berger BA , Smith LA .", "label": "", "metadata": {}, "score": "65.62277"}
{"text": "Future challenges .Given the intensity of the intervention and facilitated pathways to higher doses of combination antihypertensive treatment , these data highlight critical questions around the application of more stringent blood pressure targets in high risk people - that is , those with established cardiovascular disease or renal disease .", "label": "", "metadata": {}, "score": "65.63677"}
{"text": "Taking or , needing to take atorvastatin over than 20mg / d or any other equivalent statin ( such as simvastatin 20mg / d , pravastatin 40mg / d , fluvastatin 80mg / d or rosuvastatin 5mg / d ) in the next 6 months , or needing to take fibrates simultaneously according to investigators ' judgment .", "label": "", "metadata": {}, "score": "65.66006"}
{"text": "ARCHINTERNMED.COM 759 \u00a9 2009 American Medical Association .All rights reserved .Page 4 .EFFECT OF THE INTERVENTION Ninety percent of all events occurred in the compli- catedstratumand10%intheuncomplicatedstratum .", "label": "", "metadata": {}, "score": "65.732254"}
{"text": "16However , at this time current guidelines are based on clinic blood pressure measurements and the study reflects current clinical practice in most countries .", "label": "", "metadata": {}, "score": "65.763"}
{"text": "Data sources and searches .A systematic literature search for randomized controlled trials ( RCTs ) on MEDLINE , PubMed EMBASE , Web of Science , and the Cochrane Central Register of Controlled Trials , from their inception until July 2012 was conducted ( with an update performed in September 2013 ) .", "label": "", "metadata": {}, "score": "65.809326"}
{"text": "Furtherstud- ies are needed to confirm this finding .Trial Registration : clinicaltrials.gov Identifiers : NCT00388622 and NCT00388817 Arch Intern Med .ARCH INTERN MED / VOL 169 ( NO . 8) , APR 27 , 2009WWW .", "label": "", "metadata": {}, "score": "65.86093"}
{"text": "Searches of the electronic databases identified 480 potential citations .After initial screening of titles and abstracts , 130 full - text studies were assessed for eligibility and five RCTs [ 14 - 18 ] , all published in the English language , met the inclusion criteria .", "label": "", "metadata": {}, "score": "66.0003"}
{"text": "The administration of intravenous glucocorticoids prior to Rituxan infusions reduced the incidence and severity of such reactions , however , there was no clear benefit from the administration of oral glucocorticoids for the prevention of acute infusion reactions .", "label": "", "metadata": {}, "score": "66.27256"}
{"text": "The study will be conducted at about 54 centers in China .Data will be collected on 2,100 NSTE or SAP patients undergoing PCI .Primary outcome : MACE within 30 days after PCI .", "label": "", "metadata": {}, "score": "66.37428"}
{"text": "2003 ; 10(2):115 - 128 .Burton MM , Hope C , Murray MD , Hui S , Overhage JM .The cost of adverse drug events in ambulatory care .", "label": "", "metadata": {}, "score": "66.66046"}
{"text": "At approximately 30 weeks after initiating OCA therapy , a CT scan showed improved fatty liver in this patient .The laboratory results from this patient 's visit approximately 60 weeks after initiating OCA therapy showed an improved lipid profile , normalized liver enzymes , and improved glycosylated hemoglobin , an assessment of diabetes control .", "label": "", "metadata": {}, "score": "66.78582"}
{"text": "Statistical analysis : Ritchey , Wu , and Tu .Obtained funding : Murray .Study supervision : Murray .Financial Disclosure : None reported .", "label": "", "metadata": {}, "score": "66.905815"}
{"text": "Shares of high - flyer Intercept Pharmaceuticals ( ICPT - Get Report ) fell 16 % to $ 389 in Friday 's after - hours trading session following the disclosure of cardiac adverse events reported in a study of fatty liver disease patients involving the company 's experimental drug OCA .", "label": "", "metadata": {}, "score": "66.99109"}
{"text": "The incidence of serious infections was 2 % in the Rituxan - treated patients and 1 % in the placebo group .In the experience with Rituxan in 2578 RA patients , the rate of serious infections was 4.31 per 100 patient years .", "label": "", "metadata": {}, "score": "67.00021"}
{"text": "Approximately five weeks after initiating OCA therapy , she developed a urinary tract infection and urosepsis , which is caused by a bacterial infection that spreads throughout the body via the bloodstream and can rapidly lead to multiple organ failure and death .", "label": "", "metadata": {}, "score": "67.0921"}
{"text": "Participating in other interventional clinical trails using drugs or devices .Patients with any condition which , in the investigator 's judgment , might increase the risk to the subject for any adverse event or abnormal laboratory finding .", "label": "", "metadata": {}, "score": "67.18944"}
{"text": "The risk of bleeding in open heart surgery or surgery on the main blood vessels in the body is high .Fresh frozen plasma is sometimes administered to these patients to reduce bleeding .", "label": "", "metadata": {}, "score": "67.29385"}
{"text": "Relapsed or Refractory , Low - Grade NHL .Adverse reactions in Table 1 occurred in 356 patients with relapsed or refractory , low - grade or follicular , CD20-positive , B - cell NHL treated in single - arm studies of Rituxan administered as a single agent [ See Clinical Studies ] .", "label": "", "metadata": {}, "score": "67.30136"}
{"text": "Cytopenias and hypogammaglobulinemia .In patients with NHL receiving rituximab monotherapy , NCI - CTC Grade 3 and 4 cytopenias were reported in 48 % of patients .", "label": "", "metadata": {}, "score": "67.344635"}
{"text": "Drug : Statin .Usual care , but statin dose should not be higher than that described in exclusion criteria .Other Names : .The study objective is to test whether 2-day high dose atorvastatin administration before PCI and 30-day continuous intensive atorvastatin treatment is superior to usual care , in terms of peri - PCI cardiovascular events , as well as 6-month prognosis .", "label": "", "metadata": {}, "score": "67.38135"}
{"text": "Stewart S , Carrington MJ , Swemmer C , Kurstjens N , Jennings GL .Optimising management of hypertension in primary care : the Valsartan Intensified Primary Care Reduction of Blood Pressure ( Viper - Bp ) Study .", "label": "", "metadata": {}, "score": "67.90146"}
{"text": "A total of 273/2578 ( 11 % ) patients with RA tested positive for HACA at any time after receiving Rituxan .HACA positivity was not associated with increased infusion reactions or other adverse reactions .", "label": "", "metadata": {}, "score": "68.01918"}
{"text": "Usual care for CHD involved routine care performed by a nurse , physician , and dispensing pharmacist .Pharmacist care in this study refers to enhanced pharmacist care provided by a clinical pharmacist , hospital pharmacist , community pharmacist , or pharmacy pharmacist .", "label": "", "metadata": {}, "score": "68.02011"}
{"text": "Presumably , Intercept will make a public announcement of the final FLINT study results at that time , although the 10-K does n't say specifically .", "label": "", "metadata": {}, "score": "68.07317"}
{"text": "All rights reserved .Page 2 . interventionshavetestedtheeffectofpharmacistsonin- cident events in outpatients .We therefore determined the effect of pharmacist intervention on incident ADEs and MEs in outpatients with heart failure or hyperten- sion receiving care in a city - county health care system .", "label": "", "metadata": {}, "score": "68.15904"}
{"text": "Studies on the activities of the clinical pharmacist in an inpatient ward in resource constrained settings are scarce , however .To assess ward based clinical pharmacy services in an internal medicine ward of Jimma University Specialized Hospital .", "label": "", "metadata": {}, "score": "68.220825"}
{"text": "Firstly , we wanted to avoid potential imbalances between the groups when using a larger unit of randomisation ( that is , a general practice ) .", "label": "", "metadata": {}, "score": "68.3017"}
{"text": "3 mEq / L Hyperkalemia , serum potassium ?5.5 mEq / L Potassium - sparing diuretic and hyperkalemia Thiazide diuretic and hypokalemia ACE inhibitor and hyperkalemia Sodium polystyrene sulfonate Cardiovascular ACE inhibitor allergy ARB prescribed to replace ACE inhibitor Digoxin ? 1.7 ng / mL Antihypertensive drug and dizziness Nitrates and hypotension ? -Blocker and bradycardia Risk of drug - induced QTc interval prolongation Liver / Kidney Elevated liver enzyme levels Acetaminophen ?", "label": "", "metadata": {}, "score": "68.46466"}
{"text": "Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "68.81563"}
{"text": "Postmarketing Experience .The active agent in CYCLOSET ( bromocriptine mesylate ) has been used in other formulations and often multiple times per day to treat hyperprolactinemia , acromegaly , and Parkinson 's disease .", "label": "", "metadata": {}, "score": "68.83548"}
{"text": "Postmarketing Experience .Because these reactions are reported voluntarily from a population of uncertain size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "68.8657"}
{"text": "Examples of relevant events included angio- tensin - converting enzyme ( ACE ) inhibitor - related allergy or cough , toxicserumdigoxinconcentrations , oruseofnonsteroi- dalanti - inflammatorydrugsinpersonswithelevatedserumpo- tassium concentrations or renal insufficiency .", "label": "", "metadata": {}, "score": "69.13492"}
{"text": "Official Title : .Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI ) .Elevation of ALT , AST and CK [ Time Frame : 6 months after PCI ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "69.47777"}
{"text": "Our reasoning was that there would be future benefits of pharmacist activities to im- prove the quality and safety of medication use .Itispossiblethatinterventionssuchasourscouldhave favorableeffectsonthecostsofcare .", "label": "", "metadata": {}, "score": "70.21564"}
{"text": "Objectives : .To evaluate the risk to benefit ratio of FFP transfusion in cardiovascular surgery for the treatment of bleeding patients or for prophylaxis against bleeding .", "label": "", "metadata": {}, "score": "70.34298"}
{"text": "The rate of myocardial infarction ( MI ) was 0.56 per 100 patient years ( 28 events in 26 patients ) , which is consistent with MI rates in the general RA population .", "label": "", "metadata": {}, "score": "70.36658"}
{"text": "Allergic or experienced serious adverse reaction to HMG - CoA reductase , or ineligible to take statin as investigator 's judgment .Severe aortic valve stenosis or severe mitral stenosis , Obstructive hypertrophic cardiomyopathy , pericardial diseases .", "label": "", "metadata": {}, "score": "70.38664"}
{"text": "In RA Study 2 , where all patients initially received Rituxan , the safety profile of patients who were retreated with Rituxan was similar to those who were retreated with placebo [ See Clinical Studies , and DOSAGE AND ADMINISTRATION ] .", "label": "", "metadata": {}, "score": "70.69489"}
{"text": "Hypertension is the leading risk factor for cardiovascular disease worldwide and one of the most common conditions managed in primary care .Despite effective drug treatments , a substantial proportion of affected people remain above their ideal blood pressure target .", "label": "", "metadata": {}, "score": "70.78556"}
{"text": "Carotid plaque build - up that appears dark on ultrasound and has a low gray scale median ( GSM ) level is unstable and may rupture or burst .", "label": "", "metadata": {}, "score": "71.00568"}
{"text": "All rights reserved .Page 3 .OurcriteriaforpotentialADEswere similar to those described by Poon and colleagues25for an inpa- tient study .Medication errors were mistakes made in prescrib- ingordrugmonitoring .", "label": "", "metadata": {}, "score": "71.8432"}
{"text": "Hematologic : prolonged pancytopenia , marrow hypoplasia , Grade 3 - 4 prolonged or late - onset neutropenia , hyperviscosity syndrome in Waldenstrom 's macroglobulinemia , prolonged hypogammaglobulinemia [ See WARNINGS AND PRECAUTIONS ] .", "label": "", "metadata": {}, "score": "71.97284"}
{"text": "The recommended dose of Cycloset is 1.6 mg to 4.8 mg administered once daily within two hours after waking .Tell your doctor all medications and supplements you use .", "label": "", "metadata": {}, "score": "72.25525"}
{"text": "No cases of cardiac valvulopathy have been reported in any of the clinical studies to date with CYCLOSET .Psychotic and Psychiatric Disorders .Psychotic disorders have been reported with bromocriptine .", "label": "", "metadata": {}, "score": "72.269485"}
{"text": "As with all therapeutic proteins , there is a potential for immunogenicity .The observed incidence of antibody ( including neutralizing antibody ) positivity in an assay is highly dependent on several factors including assay sensitivity and specificity , assay methodology , sample handling , timing of sample collection , concomitant medications , and underlying disease .", "label": "", "metadata": {}, "score": "72.51807"}
{"text": "Abbreviations : ACE angiotensin - converting enzyme .Blood pressure ( BP ) control .Two studies reported the number of patients who achieved BP control target values [ 15 , 17 ] .", "label": "", "metadata": {}, "score": "72.59877"}
{"text": "( % )b Other insurance , No .( % )No insurance , No .( % )Comorbidities , mean ( SD ) , No .", "label": "", "metadata": {}, "score": "72.76199"}
{"text": "[See WARNINGS AND PRECAUTIONS ] .In randomized , controlled studies where Rituxan was administered following chemotherapy for the treatment of follicular or low - grade NHL , the rate of infection was higher among patients who received Rituxan .", "label": "", "metadata": {}, "score": "72.781906"}
{"text": "The Australian universal health insurance scheme ( Medicare ) provides citizens with free access to public hospitals and reimbursed access ( 70 % of services with no co - payment ) to a widespread network of primary care or general practice clinics .", "label": "", "metadata": {}, "score": "72.94075"}
{"text": "Encounterswere any visit made to the health system requiring registration .Co- morbidities included any chronic disorder for which a medi- cation would likely be prescribed .", "label": "", "metadata": {}, "score": "72.979706"}
{"text": "Among several studies investigating a possible relation between bromocriptine exposure and cardiac valvulopathy , some events of cardiac valvulopathy have been reported , but no definitive association between bromocriptine mesylate use and clinically significant ( moderate to severe ) cardiac valvulopathy could be concluded .", "label": "", "metadata": {}, "score": "73.22354"}
{"text": "References .Lloyd - Jones DM , Hong Y , Labarthe D , Mozaffarian D , Appel LJ , Van Horn L , Greenlund K , Daniels S , Nichol G , Tomaselli GF , et al .", "label": "", "metadata": {}, "score": "73.33801"}
{"text": "DRUG INTERACTIONS .Formal drug interaction studies have not been performed with Rituxan .In patients with CLL , Rituxan did not alter systemic exposure to fludarabine or cyclophosphamide .", "label": "", "metadata": {}, "score": "73.59534"}
{"text": "The median duration of lymphopenia was 14 days ( range , 1 - 588 days ) and of neutropenia was 13 days ( range , 2 - 116 days ) .", "label": "", "metadata": {}, "score": "73.82405"}
{"text": "The study population had a mean baseline age of 60 years ( range 27 - 80 ) and 33 % were 65 years of age or older .", "label": "", "metadata": {}, "score": "74.03377"}
{"text": "PubMed .Straka RJ , Taheri R , Cooper SL , Smith JC : Achieving cholesterol target in a managed care organization ( ACTION ) trial .", "label": "", "metadata": {}, "score": "74.1881"}
{"text": "Circulation 2010 , 121 ( 4 ) : 586 - 613 .PubMed View Article .Hamm CW , Bassand JP , Agewall S , Bax J , Boersma E , Bueno H , Caso P , Dudek D , Gielen S , Huber K , et al .", "label": "", "metadata": {}, "score": "74.61966"}
{"text": "PubMed View Article .Smith SC Jr , Allen J , Blair SN , Bonow RO , Brass LM , Fonarow GC , Grundy SM , Hiratzka L , Jones D , Krumholz HM , et al .", "label": "", "metadata": {}, "score": "74.70897"}
{"text": "\"Determining the degree of stenosis , or how much the artery has narrowed , is insufficient to predict patient risk , \" said lead researcher Markus Reiter , M.D. , from the Department of Angiography and Interventional Radiology at Medical University Vienna in Austria .", "label": "", "metadata": {}, "score": "74.7339"}
{"text": "Neuroleptic -like Malignant Syndrome .A neuroleptic -like malignant syndrome ( manifested by high fever and increase in creatinine phosphokinase ) has been reported upon cessation of bromocriptine treatment in patients with advanced Parkinson 's disease or patients with secondary Parkinsonism .", "label": "", "metadata": {}, "score": "74.75891"}
{"text": "This is the latest ...LaFortune , Executive Vice President at Demers .( Date:2/12/2016 ) ... -- HeartWare International , Inc .( NASDAQ : HTWR ) ... its financial results for the three and 12 months ... at 8:00 a.m. ET .", "label": "", "metadata": {}, "score": "75.40598"}
{"text": "Table 2 shows absolute blood pressure values ( with change in blood pressure from baseline ) and overall pattern of blood pressure control for both groups during progressive visits .", "label": "", "metadata": {}, "score": "75.56668"}
{"text": "Findings from the GIANT trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics ( TCT ) scientific symposium .Sponsored by the Cardiovascular Research Foundation ( CRF ) , TCT is the world 's premier educational meeting specializing in interventional cardiovascular medicine .", "label": "", "metadata": {}, "score": "75.961975"}
{"text": "Funding :The VIPER - BP study was sponsored by Novartis Pharmaceuticals Australia .The sponsors participated in discussions on the design and conduct of the study and provided logistical support during the trial .", "label": "", "metadata": {}, "score": "76.59442"}
{"text": "Codeddatawereavailableforbothstud- ies ; however , we had access to text data only for the heart fail- urestudy .Computerprogramswererunbyprogrammersblinded totreatmentgroupassignmentafterpatientshadcompletedtheir full participation in the trials .", "label": "", "metadata": {}, "score": "77.02289"}
{"text": "aParticipants from both heart failure and hypertension studies .bAll heart failure study participants and complicated hypertension participants .cHypertension participants in the uncomplicated stratum of the hypertension study .", "label": "", "metadata": {}, "score": "77.15195"}
{"text": "( % )Insufficient household income , No .( % ) Married , No .( % )Medicare , No .( % ) Medicaid , No .", "label": "", "metadata": {}, "score": "77.1521"}
{"text": "The authors declare that they have no competing interests .Author 's contributions .HX and HC designed the study , collected and analyzed the data , drafted the manuscripts , and are the guarantors of this study .", "label": "", "metadata": {}, "score": "77.45441"}
{"text": "Cycloset is not expected to harm a fetus .However , a pituitary tumor in the mother can expand during pregnancy .High blood pressure can also occur during pregnancy and this drug could be dangerous if taken by a pregnant woman with high blood pressure .", "label": "", "metadata": {}, "score": "77.73309"}
{"text": "Stroke .The indication for use of bromocriptine for inhibition of postpartum lactation was withdrawn based on postmarketing reports of stroke .Causality of bromocriptine use and the occurrence of stroke in this patient population has not been proven .", "label": "", "metadata": {}, "score": "78.04271"}
{"text": "Since patients with RA are at increased risk for cardiovascular events compared with the general population , patients with RA should be monitored throughout the infusion and Rituxan should be discontinued in the event of a serious or life - threatening cardiac event .", "label": "", "metadata": {}, "score": "78.09799"}
{"text": "( Date:2/12/2016 ) ...NY , Feb. 12 , 2016 /PRNewswire/ - Demers Ambulances announces ... to Okaloosa County Emergency ...Type III ambulances and one LT2 van .", "label": "", "metadata": {}, "score": "78.106"}
{"text": "Adherence to aspirin and \u03b2 - blocker were reported in two studies [ 14 , 15 ] , lipid - lowering drug in five studies [ 14 - 18 ] , and an ACE inhibitor in one study [ 15 ] .", "label": "", "metadata": {}, "score": "78.73317"}
{"text": "October 11 , 2007:90 - 93 .ARCH INTERN MED / VOL 169 ( NO . 8) , APR 27 , 2009WWW .ARCHINTERNMED.COM 763 \u00a9 2009 American Medical Association .", "label": "", "metadata": {}, "score": "79.3176"}
{"text": "Acquisition of data : Murray .Analysis and in- terpretationofdata : Murray , Ritchey , Wu , andTu .Draft- ing of the manuscript : Murray , Ritchey , and Tu .", "label": "", "metadata": {}, "score": "79.69264"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "79.781975"}
{"text": "Ultrasound Used to Predict Heart Attack Risk .OAK BROOK , Ill. - Repeat exams using widely available and inexpensive ultrasound imaging could help identify patients at high risk for a heart attack or other adverse cardiovascular events , according to a study published in the September issue of the journal Radiology .", "label": "", "metadata": {}, "score": "79.79407"}
{"text": "Conclusions In a primary care setting intensive structured care resulted in higher levels of blood pressure control , with clinically lower blood pressure and absolute risk of future cardiovascular events overall and with more people achieving their target blood pressure .", "label": "", "metadata": {}, "score": "79.93086"}
{"text": "Baseline and outcome data were analysed using SPSS for Windows version 19.0 .Continuous data are presented as means ( standard deviations ) or medians ( interquartile ranges ) .", "label": "", "metadata": {}, "score": "80.47374"}
{"text": "Circulation 2006 , 113 ( 19 ) : 2363 - 2372 .PubMed View Article .Smith SC Jr , Benjamin EJ , Bonow RO , Braun LT , Creager MA , Franklin BA , Gibbons RJ , Grundy SM , Hiratzka LF , Jones DW , et al .", "label": "", "metadata": {}, "score": "80.55349"}
{"text": "Keywords .Coronary heart disease Pharmacist Secondary prevention Mortality Medication adherence .Background .Coronary heart disease ( CHD ) is one of the leading causes of morbidity and mortality in the world [ 1 ] .", "label": "", "metadata": {}, "score": "80.56092"}
{"text": "Hypogammaglobulinemia .Hypogammaglobulinemia ( IgA , IgG or IgM below the lower limit of normal ) has been observed in patients with GPA and MPA treated with Rituxan .", "label": "", "metadata": {}, "score": "81.57132"}
{"text": "2testsforcat- egorical variables with a P value less than .05 considered sta- tisticallysignificant .The ?2orFisherexacttestswerealsoused to test the hypotheses that the ADEs and MEs among partici- pants were independent of intervention or control group as- signment .", "label": "", "metadata": {}, "score": "82.256256"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01293097 .Angina Pectoris Angina , Stable Angina , Unstable Coronary Artery Disease Coronary Disease Myocardial Infarction Myocardial Ischemia Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Chest Pain Heart Diseases Pain .", "label": "", "metadata": {}, "score": "82.49338"}
{"text": "For Patients .Cycloset ( bromocriptine mesylate ) is a dopamine receptor agonist used together with diet and exercise to treat type 2 ( non-insulin dependent ) diabetes .", "label": "", "metadata": {}, "score": "83.00864"}
{"text": "Art .No . : CD007614 .DOI : 10.1002/14651858 .CD007614.pub2 .Cochrane Review - How can it help you ?For 20 years , Cochrane has produced systematic reviews of primary research in human health care and health policy , and are internationally recognized as the highest standard in evidence - based health care resources .", "label": "", "metadata": {}, "score": "83.62899"}
{"text": "Hypophosphatemia was more common in patients who received corticosteroids .In the experience with Rituxan in RA patients , newly - occurring hypophosphatemia was observed in 21 % ( 528/2570 ) of patients and newly - occurring hyperuricemia was observed in 2 % ( 56/2570 ) of patients .", "label": "", "metadata": {}, "score": "83.887474"}
{"text": "Mean systolic and diastolic blood pressure and absolute change from baseline by study visits .Values are means ( standard deviations ) unless stated otherwise .", "label": "", "metadata": {}, "score": "84.163025"}
{"text": "All rights reserved .Page 7 .Inthissamehealth care setting , Burton et al32recentlydetermined that the mean charge for an ADE was $ 926 in 2006 dollars .", "label": "", "metadata": {}, "score": "86.40787"}
{"text": "12 Discipline of General Practice , University of Adelaide , Adelaide , SA , Australia .Abstract .Objective To determine the effectiveness of intensive structured care to optimise blood pressure control based on individual absolute risk targets in primary care .", "label": "", "metadata": {}, "score": "86.92969"}
{"text": "Read the full abstract ... .Background : .Fresh frozen plasma ( FFP ) is a blood component containing procoagulant factors , which is sometimes used in cardiovascular surgery with the aim of reducing the risk of bleeding .", "label": "", "metadata": {}, "score": "87.00295"}
{"text": "This drug lowers the hormone needed to produce breast milk .Do not breastfeed while taking Cycloset .Our Cycloset ( bromocriptine mesylate ) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication .", "label": "", "metadata": {}, "score": "87.281845"}
{"text": "Intercept disclosed the new OCA safety findings in its 10-K filed Friday night .Here 's the paragraph which spooked investors and caused the stock to fall : .", "label": "", "metadata": {}, "score": "87.54452"}
{"text": "\" These findings may help determine alternative treatment strategies for patients identified as CYP2C19 poor metabolizers .\" This year 's Au Pair of the Year ... .", "label": "", "metadata": {}, "score": "88.55113"}
{"text": "Cycloset .\" Researchers at the National Institutes of Health have clarified in rodent and test tube experiments the role that inflammation plays in type 2 diabetes , and revealed a possible molecular target for treating the disease .", "label": "", "metadata": {}, "score": "88.77744"}
{"text": "Fresh frozen plasma for patients undergoing surgery on the heart or blood vessels .Fresh frozen plasma is obtained from whole blood from blood donors .", "label": "", "metadata": {}, "score": "88.826416"}
{"text": "20 \u00b5g / mL ?SI conversion factors : To convert potassium to millimoles per liter , multiply by 1.0 ; ALT to microkatals per liter , multiply by 0.0167 ; glucose to millimoles per liter , multiply by 0.0555 ; digoxin to nanomoles per liter , multiply by 1.281 .", "label": "", "metadata": {}, "score": "89.60597"}
{"text": "February 12 , 2016 , ...The law firm of Morrow , ...Parishes .The purpose of these scholarships is to encourage applicants to pursue a ... seek employment within these two parishes . , \" We have available jobs in St. ... .", "label": "", "metadata": {}, "score": "89.98828"}
{"text": "ARCH INTERN MED / VOL 169 ( NO . 8) , APR 27 , 2009WWW .ARCHINTERNMED.COM 760 \u00a9 2009 American Medical Association .All rights reserved .", "label": "", "metadata": {}, "score": "91.7702"}
{"text": "VIPER - BP study was supported by the Victoria government 's operational infrastructure support program .Ethical approval : This study was approved by the Alfred Human Research Ethics Committee ( Melbourne Australia ; Project No 358/08 ) and the Royal Australian College of General Practitioners ( Melbourne Australia ; Project No NREEC 09/006 ) .", "label": "", "metadata": {}, "score": "92.195786"}
{"text": "Accepted for Publication : December 23 , 2008 .Correspondence : Michael D. Murray , PharmD , MPH , EshelmanSchoolofPharmacy , UniversityofNorthCaro- lina at Chapel Hill , CB 7360 , Kerr Hall , Room 2212 , Chapel Hill , NC 27599 - 7360 ( mick@unc.edu ) .", "label": "", "metadata": {}, "score": "92.567055"}
{"text": "Acknowledgements .The authors thank the Zhejiang Pharmaceutical Society ( 2011ZYY01 ) , China for the hospital pharmacy special research fund to carry out this project .", "label": "", "metadata": {}, "score": "92.9176"}
{"text": "Please click on the link within the confirmation email previously sent you to complete registration .Need a new registration confirmation email ?Click here .", "label": "", "metadata": {}, "score": "94.09318"}
{"text": "The Radiological Society of North America ( RSNA ) is an association of more than 41,000 radiologists , radiation oncologists , medical physicists and related scientists committed to excellence in patient care through education and research .", "label": "", "metadata": {}, "score": "94.57464"}
{"text": "( PRWEB ) , ... February 12 , 2016 , ...Each year , ... will be held in Anaheim , CA at the Anaheim Convention Center .", "label": "", "metadata": {}, "score": "96.45392"}
{"text": "Adam Feuerstein writes regularly for TheStreet .In keeping with company editorial policy , he does n't own or short individual stocks , although he owns stock in TheStreet .", "label": "", "metadata": {}, "score": "98.36587"}
{"text": "mentofADEsandMEsweresecondarystudyobjectives .Details oftheoriginalstudieshavebeenpreviouslydescribed.14,18,19The studieswereapprovedbytheinstitutionalreviewboardsofIn- diana University - Purdue University at Indianapolis , Indiana , and the University of North Carolina at Chapel Hill .STUDY SETTING AND PARTICIPANTS Participantsforbothtrialswererecruitedattheoutpatientprac- ticesofWishardHealthServices , Indianapolis , Indiana .", "label": "", "metadata": {}, "score": "100.029144"}
{"text": "Abbreviations : BP blood pressure , CKD chronic kidney disease , CVD cardiovascular disease , HDL - C high - density lipoprotein cholesterol , LDL - C low - density lipoprotein cholesterol .", "label": "", "metadata": {}, "score": "104.55515"}
{"text": "( Date:2/12/2016 ) ... , Feb. 12 , 2016 Diplomat Pharmacy , Inc. ( NYSE : DPLO ) is pleased to announce ...Management and Payor Strategies effective Jan. 23 , 2016 . ... ... ...", "label": "", "metadata": {}, "score": "108.008545"}
{"text": "PubMed View Article .Pre - publication history .Copyright .\u00a9 Cai et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. RSNA Press Release .", "label": "", "metadata": {}, "score": "112.53096"}
